BRKR
NASDAQBruker Corporation
SectorIndustrialsIndustryBiotechnology: Laboratory Analytical Instruments
Price$56.75-0.47 (-0.82%)
01:30 PM03:15 PM
News · 26 weeks60+280%
2026-03-012026-08-23
Mix3290d
- Insider16(50%)
- Other7(22%)
- SEC Filings5(16%)
- Earnings2(6%)
- Analyst1(3%)
- M&A1(3%)
Latest news
25 items- INSIDERChief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPresident BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDERPRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 6,925 shares, decreasing direct ownership by 0.02% to 38,487,178 units (SEC Form 4) (withholding tax)4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 3,477 shares, decreasing direct ownership by 3% to 124,966 units (SEC Form 4) to satisfy withholding obligation4 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 2,889 shares, decreasing direct ownership by 3% to 99,694 units (SEC Form 4) to satisfy withholding obligation4 - BRUKER CORP (0001109354) (Issuer)
- PRBruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving LaboratoriesEnables deeper integration of Atinary's SDLabs platform with Chemspeed automation, Bruker instruments and SciY software for closed-loop agentic AI-driven R&D Bruker Corporation (NASDAQ:BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811179936/en/Atinary Self-Driving Lab integrating Chemspeed robotics, a Fourier 80
- PRBruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and DevelopmentMIMETAS’ unique organ-on-a-chip and human tissue models complement Bruker’s multiomics, NMR, spatial biology and preclinical imaging solutions Bruker Corporation (NASDAQ:BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems. This press release features multimedia. View the full release he
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bruker CorporationSCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
- SECSEC Form 10-Q filed by Bruker Corporation10-Q - BRUKER CORP (0001109354) (Filer)
- SECBruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Reports Second Quarter 2026 Financial ResultsQ2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding tariff refunds Q2-26 GAAP diluted loss per share of $(0.41); non-GAAP diluted earnings per share (EPS) $0.49 Updating FY2026 guidance for currency and tax only: Revenues of $3.54 to $3.57 billion, up 3% to 4% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented:
- SECBruker Corporation filed SEC Form 8-K: Other Events8-K - BRUKER CORP (0001109354) (Filer)
- PRBruker Announces Date and Time of Second Quarter 2026 Earnings Release and WebcastBruker Corporation (NASDAQ:BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q2 2026 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll fr
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $120,500 worth of shares (2,000 units at $60.25) as part of a pre-agreed trading plan (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
- PRBruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in BloodBruker Corporation (NASDAQ:BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samplesDISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and appl
- INSIDERNew insider Pusch Wolfgang claimed ownership of 10,154 shares (SEC Form 3)3 - BRUKER CORP (0001109354) (Issuer)
- INSIDEREXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $109,520 worth of shares (2,000 units at $54.76) as part of a pre-agreed trading plan (SEC Form 4)4 - BRUKER CORP (0001109354) (Issuer)
BRKR FAQ
7 questionsWhat does Bruker Corporation do?
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy...Where does BRKR stock trade?
Bruker Corporation (BRKR) is listed on NASDAQ.What sector and industry is BRKR in?
Bruker Corporation operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.Does BRKR pay a dividend?
BRKR's most recent ex-dividend date was 2026-06-22 with a cash dividend of $0.05 per share. No future ex-date is on file yet.What are analysts saying about BRKR?
Bruker Corporation has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets cluster around $4000.00.What companies are similar to BRKR?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare BRKR side-by-side with any of them on Quantisnow.How can I track BRKR on Quantisnow?
Quantisnow aggregates Bruker Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRKR to receive live email and push alerts on every new disclosure.